Clinical trial details

A First-in-human, Open-label Dose Escalation Followed by Dose Expansion Phase I/IIa Trial to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Intratumoral CyPep-1 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Cancers.

Identifier

CyPep-1/SMS-0571/CICILIA

Sponsor

ACYTOVATION ASA

Principal Investigator

ELENA GARRALDA CABANAS

Service

Oncology

Study details

Tumor type: ALL SOLID TUMORS
Stage: Advanced
Main Investigational Agent : Other
Phase: I
Randomization: Non-randomized

Molecular details

Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: Not applicable

Drug details

Arm A: CyPep-1
Arm B: CyPep-1 and Pembrolizumab

Links

Clinical Trials GOV (NCT identifier): NL
EU Clinical Trials Register (eudraCT Identifier): 2019-003317-33